Travere Therapeutics Inc
(TVTX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 233,175 | 145,238 | 109,460 | 131,836 | 198,321 |
| Cost of Goods | 7,744 | 11,450 | 4,420 | 3,818 | 6,126 |
| Gross Profit | 225,431 | 133,788 | 105,040 | 128,018 | 192,195 |
| Operating Expenses | 550,002 | 522,376 | 425,273 | 328,261 | 368,484 |
| Operating Income | -323,827 | -388,138 | -319,813 | -199,425 | -176,163 |
| Interest Expense | 11,182 | 11,334 | 11,014 | 19,682 | 19,050 |
| Other Income | 14,499 | 23,362 | -328 | 2,224 | 6,423 |
| Pre-tax Income | -320,510 | -376,110 | -331,155 | -216,883 | -188,790 |
| Income Tax | 120 | 223 | 313 | 409 | -19,359 |
| Net Income Continuous | -320,630 | -376,333 | -331,468 | -217,292 | -169,431 |
| Net Income Discontinuous | -915 | 264,934 | 52,986 | 37,201 | N/A |
| Net Income | $-321,545 | $-111,399 | $-278,482 | $-180,091 | $-169,431 |
| EPS Basic Total Ops | -4.08 | -1.50 | -4.37 | -3.01 | -3.56 |
| EPS Basic Continuous Ops | -4.07 | -5.07 | -5.20 | -3.63 | -3.56 |
| EPS Basic Discontinuous Ops | -0.01 | 3.57 | 0.83 | 0.62 | N/A |
| EPS Diluted Total Ops | -4.08 | -1.50 | -4.37 | -3.01 | -3.56 |
| EPS Diluted Continuous Ops | -4.07 | -5.07 | -5.20 | -3.63 | -3.56 |
| EPS Diluted Discontinuous Ops | -0.01 | 3.57 | 0.83 | 0.62 | N/A |
| EPS Diluted Before Non-Recurring Items | -4.07 | -5.07 | -4.37 | -3.01 | -3.56 |
| EBITDA(a) | $-283,082 | $-355,346 | $-298,172 | $-173,429 | $-141,106 |